Estimate of the cost of multiple sclerosis in Spain by literature review

References

• Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502–17.
   PubMed Web of Science ®Google Scholar
• Real Patronato sobre Discapacidad. Esclerosis Múltiple en España: realidad, necesidades sociales y calidad de vida [Esclerosis Múltiple en España: realidad, necesidades sociales y calidad de vida]. Madrid: ICONO Imagen Gráfica, S.A; 2007. Available from: http://www.esclerosismultiple.com/pdfs/estudio%20calidad%20de%20vida.pdf. Spanish
   Google Scholar
• Otero-Romero S, Roura P, Solá J, et al. Increase in the prevalence of multiple sclerosis over a 17-year period in Osona, Catalonia, Spain. Mult Scler. 2013;19:245–248.
   PubMed Web of Science ®Google Scholar
• Fernández O, Fernández V, Guerrero M, et al. Multiple sclerosis prevalence in Malaga, Southern Spain estimated by the capture-recapture method. Mult Scler. 2012;18:372–376.
   PubMed Web of Science ®Google Scholar
• Bartulos M, Marzo ME, Estrella LA, et al. [Epidemiological study of multiple sclerosis in La Rioja.]. Neurologia. 2015;30:552–560. Spanish.
   PubMed Web of Science ®Google Scholar
• Carreón-Guarnizo E, Andreu-Reinon E, Cerdan-Sanchez M, et al. [Prevalence of multiple sclerosis in the Region of Murcia]. Rev Neurol. 2016;62:396–402. Spanish.
   PubMed Web of Science ®Google Scholar
• Izquierdo G, Venegas A, Sanabria C, et al. Long-term epidemiology of multiple sclerosis in the Northern Seville District. Acta Neurol Scand. 2015;132:111–117.
   PubMed Web of Science ®Google Scholar
• Multiple Sclerosis International Federation. Atlas of MS 2013. Mapping multiple sclerosis around the world. London: Summers Editorial & Design; 2013. Available from: https://www.msif.org/about-us/advocacy/atlas/?gclid=CNDP8My2qtACFQsR0wod58ENUw.
   Google Scholar
• Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National multiple sclerosis society (USA) advisory committee on clinical trials of new agents in multiple sclerosis. Neurology. 1996;46:907–911.
   PubMed Web of Science ®Google Scholar
• De Lorenzo-Pinto A, Rodríguez-González CG, Ais-Larisgoitia A. Nuevos tratamientos para la esclerosis múltiple. [Emerging therapies for multiple sclerosis]. Med Clin (Barc). 2013;140: 76–82. Spanish.
   PubMed Web of Science ®Google Scholar
• Arnett P, Forn C. [Neuropsychological evaluation in multiple sclerosis]. Rev Neurol. 2007;44: 166–172. Spanish.
   PubMed Web of Science ®Google Scholar
• Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries. Mult Scler. 2012;18(2 Suppl):7–15.
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–1452.
   PubMed Web of Science ®Google Scholar
• De Sa JC, Airas L, Bartholome E, et al. Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice. Ther Adv Neurol Disord. 2011;4:139–168.
   PubMedGoogle Scholar
• García A, Ara JR, Fernández O, et al. Consensus statement on the treatment of multiple sclerosis by the Spanish Society of Neurology in 2016. Neurologia. 2017;32:113–119.
   PubMed Web of Science ®Google Scholar
• Villoro R, Hidalgo A Análisis del gasto asociado a los tratamientos de esclerosis múltiple en España durante el periodo 2004-2015. [Analysis of expenditure associated with multiple sclerosis treatments in Spain during the period 2004-2015.] Poster session presented at: XXXVI Jornadas de Economía de la Salud; 2016 Jun 15-17; Murcia, Spain. Spanish.
   Google Scholar
• Boix B, Figueras M, Riera M. Cost-effectiveness of new therapies for multiple sclerosis in Spain. Value Health. 2015;18:A757.
   PubMed Web of Science ®Google Scholar
• Villoro R, Hidalgo A. Analysis of expenditure in multiple sclerosis disease modifying therapies evolution between 2004-2014 in Spain. Value Health. 2015;18:A755.
   PubMed Web of Science ®Google Scholar
• Oyagüez I, Echave M, Gómez M, et al. Análisis coste efecitvidad de natalizumab frente a fingolimod en pacientes con esclerosis múltiple remitente recurrente de alta actividad. [Cost-effectiveness analysis of natalizumab versus fingolimod in patients with highly active relapsing-remitting multiple sclerosis].Poster session presented at: XXXV Jornadas de Economía de la Salud. 2015 Jun 17-19; Granada, Spain. Spanish.
   Google Scholar
• Piñol C. Cost-effectiveness analysis of interferon beta-1b as treatment for patients with clinically isolated syndrome suggestive of multiple sclerosis in Spain. Neurologia. 2016;31:247–254.
   PubMed Web of Science ®Google Scholar
• Van Engen A, Wu Y, Tchoukouaha T, et al. Cost of drug-related monitoring requirements for glatiramer acetate and other multiple sclerosis Disease-Modifying Therapies (Dmts). Value Health. 2015;18:A753.
   PubMed Web of Science ®Google Scholar
• Izquierdo G. Esclerosis múltiple: impacto socioeconómico y en la calidad de vida de los pacientes [Multiple sclerosis: socioeconomic effects and impact on quality of life.]. Med Clin (Barc). 2014;143(Suppl 3): 7–12. Spanish.
   PubMedGoogle Scholar
• Crespo C, Izquierdo G, García-Ruiz A, et al. Cost minimisation analysis of fingolimod vs natalizumab as a second line of treatment for relapsing-remitting multiple sclerosis. Neurologia. 2014;29:210–217.
   PubMed Web of Science ®Google Scholar
• Darbà J, Kaskens L. Sánchez de la Rosa R. Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study. J Med Econ. 2014;17:215–222.
   PubMedGoogle Scholar
• Dembek C, White LA, Quach J, et al. Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain. Eur J Health Econ. 2014;15:353–362.
   PubMed Web of Science ®Google Scholar
• Granell M, Pérez-Alcántara F, Arroyo R, et al. Coste por brote de esclerosis múltiple según gravedad en España. [Cost per multiple sclerosis relapse according to severity in Spain] Presented at: XXXIV Jornadas de Economía de la Salud. 2014 May 27-30; Pamplona, Spain. Spanish.
   Google Scholar
• Villoro R, Hidalgo A. Analysis of Expenditure in multiple sclerosis disease modifying therapies evolution between 2004-2013 in Spain. Value Health. 2014;17:A396.
   PubMed Web of Science ®Google Scholar
• Parés-Badell O, Barbaglia G, Jerinic P, et al. Cost of disorders of the brain in Spain. PLoS One. 2014;9:e105471.
   PubMed Web of Science ®Google Scholar
• Pérez-Alcántara F, Granell M, Arroyo R, et al. Análisis coste-consecuencia del tratamiento de la esclerosis múltiple con fingolimod de forma temprana o tardía. [Cost-consequence analysis of treatment of multiple sclerosis with fingolimod in an early or late form] Poster session presented at: XXXIV Jornadas de Economía de la Salud. 2014 May 27-30; Pamplona, Spain. Spanish.
   Google Scholar
• Sánchez De La Rosa R, Garcia BL, Meca J. Cost analysis of the use of glatiramer acetate compared to interferon-α in patients with relapsing-remitting multiple sclerosis and spasticity in Spain. Value Health. 2014;17:A394.
   PubMed Web of Science ®Google Scholar
• Hidalgo A, Villoro R. Analysis of expenditure in multiple sclerosis disease modifying therapies evolution between 2004-2012 in Spain. Value Health. 2013;16:A629.
   PubMed Web of Science ®Google Scholar
• Sánchez De La Rosa R, Sabater E, Casado MA. Cost analysis of glatiramer acetate vs. fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain. Health Econ Rev. 2013;3:13.
   PubMedGoogle Scholar
• Aranda I, Oliva J, Hidalgo A, et al. Assessment of informal care provided to patients with multiple sclerosis and limitation of personal autonomy. Value Health. 2012;15:A550.
   PubMed Web of Science ®Google Scholar
• Balañá M, González AM, Iranzo N, et al. Carga económica y necesidades no cubiertas en el tratamiento de la esclerosis múltiple en España. [Economic burden and unmet needs in the treatment of multiple sclerosis in Spain]. Gac Sanit. 2012;26(EspecCongr 1):34–69. Spanish.
   Google Scholar
• García-Ruiz A, Izquierdo G, García-Agua N. Budgetary impact of the treatment of relapsing-remitting multiple sclerosis in Spain. Value Health. 2012;15:A548.
   Web of Science ®Google Scholar
• Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Spain. Mult Scler. 2012b;18(2 Suppl):35–39.
   PubMed Web of Science ®Google Scholar
• Oyagüez I, Casado MA, Farfan FJ, et al. Análisis de costes de natalizumab frente a fingolimod en el tratamiento de la esclerosis múltiple. [Cost analysis of natalizumab versus fingolimod in the treatment of multiple sclerosis.]. Gac Sanit. 2012;26(EspecCongr 1):34–69. Spanish.
   Google Scholar
• Polanco C, Sanz-Granda A, García-Jurado L. Pharmacological costs of recurrent-remitent multiple sclerosis treatment in Spain. Value Health. 2012;15:A549.
   Web of Science ®Google Scholar
• Sánchez De La Rosa R, Sabater E, Casado MA, et al. Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients. J Med Econ. 2012;15:424–433.
   PubMedGoogle Scholar
• Slof J, Gras A. Sativex® in multiple sclerosis spasticity: a cost-effectiveness model. Expert Rev Pharmacoecon Outcomes Res. 2012;12:439–441.
   PubMed Web of Science ®Google Scholar
• Arroyo R, Vila C, Clissold S. Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the ‘5E’ study. Expert Rev Pharmacoecon Outcomes Res. 2011;11:205–213.
   PubMed Web of Science ®Google Scholar
• Gubieras L, Casado V, Romero-Pinel L, et al. Cost of the informal care of multiple sclerosis in Spain. Value Health. 2011a;14:A321.
   Web of Science ®Google Scholar
• Gubieras L, Casado V, Romero-Pinel L, et al. Cost of the relapse of multiple sclerosis in Spain. Value Health. 2011b;14:A320.
   Web of Science ®Google Scholar
• Sánchez De La Rosa R, Sabater E, Casado MA. Análisis del impacto presupuestario del tratamiento en primera línea de la esclerosis múltiple remitente recurrente en España. [Budgetary impact analysis of first-line treatment of relapsing remitting multiple sclerosis in Spain]. Rev Neurol. 2011;53: 129–138. Spanish.
   PubMed Web of Science ®Google Scholar
• Pérez N, Rocher A, Soler E. Evolución del coste por patologías en la unidad de atención farmacéutica a pacientes externos en un departamento de la Comunidad Valenciana. [Evolution of cost for pathologies in the outpatient pharmaceutical care unit in a department of the Valencian Community]. Gac Sanit. 2010;24(EspecCongr 1): 1–2. Spanish.
   PubMed Web of Science ®Google Scholar
• Casado V, Gubieras L, Romero-Pinel L, et al. Cost of the diagnosis of EM. J Neurol. 2009;256(Suppl 2):S1–S266.
   PubMed Web of Science ®Google Scholar
• Casado V, Romero L, Gubieras L, et al. An approach to estimating the intangible costs of multiple sclerosis according to disability in Catalonia, Spain. Mult Scler. 2007;13:800–804.
   PubMed Web of Science ®Google Scholar
• Gubieras L, Casado V, Romero-Pinel, et al. Estimación del coste de los cuidados informales en la esclerosis múltiple. [Estimating the cost of informal care in multiple sclerosis] Poster sesión presented at: XXVII Jornadas de Economía de la Salud. 2007 Jun 6-8; A Coruña, Spain. Spanish.
   Google Scholar
• Oliva J, Osuna R, Jorgensen N. Estimación de los costes de los cuidados informales asociados a enfermedades neurológicas de alta prevalencia en España. [Estimation of the costs of informal care associated with neurological diseases of high prevalence in Spain] Pharmacoecon. Span Res Artic. 2007;4: 83–96. Spanish.
   Google Scholar
• Sobocki P, Pugliatti M, Lauer K, et al. Estimation of the cost of MS in Europe: extrapolations from a multinational cost study. Mult Scler. 2007;13:1054–1064.
   PubMed Web of Science ®Google Scholar
• Casado V, Martínez-Yélamos S, Martínez-Yélamos A, et al. Direct and indirect costs of multiple sclerosis in Baix Llobregat (Catalonia, Spain), according to disability. BMC Health Serv Res. 2006a;6:143.
   PubMed Web of Science ®Google Scholar
• Casado V, Martinez-Yelamos S, Martinez-Yelamos A, et al. ¿Cuánto cuesta un brote de esclerosis múltiple en Cataluña? [The costs of a multiple sclerosis relapse in Catalonia (Spain)]. Neurologia. 2006b;21:341–347. Spanish.
   PubMed Web of Science ®Google Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Spain. Eur J Health Econ. 2006;7(Suppl 2):S65–74.
   PubMedGoogle Scholar
• Izquierdo G, Medina-Redondo F. Interferón beta en la esclerosis múltiple. Estimación del coste a medio y largo plazo en relación con el beneficio del tratamiento. [Interferon beta in multiple sclerosis. Estimation of medium- and long-term cost in relation to treatment benefit]. Pharmacoecon Span Res Artic. 2005;2: 21–29. Spanish.
   Google Scholar
• Oliva J, Osuna R, Lobo F, et al. The costs of informal care in neurological disorders in Spain. Value Health. 2005;8:A131.
   Web of Science ®Google Scholar
• Rubio-Terrés C, Domínguez-Gil Hurlé A. Análisis coste-utilidad del tratamiento de la esclerosis múltiple remitente-recidivante con azatioprina o interferón beta en España. [Cost-utility analysis of relapsing-remitting multiple sclerosis treatment with azathioprine or interferon beta in Spain]. Rev Neurol. 2005;40: 705–710. Spanish.
   PubMed Web of Science ®Google Scholar
• Medina-Redondo F, Herrera-Carranza J, Sanabria C, et al. Eficiencia y relación coste-utilidad del interferón beta en la esclerosis múltiple en Andalucía. [The efficiency and cost-utility ratio of interferon beta in the treatment of multiple sclerosis in Andalusia]. Rev Neurol. 2004;39:1–6. Spanish.
   PubMed Web of Science ®Google Scholar
• Rubio-Terrés C, Arístegui I, Medina F, et al. Análisis coste-utilidad del tratamiento de la esclerosis múltiple remitente-recidivante con acetato de glatiramero o interferón beta en España. [Cost-utility analysis of multiple sclerosis treatment with glatiramer acetate or interferon beta in Spain]. Farm Hosp. 2003;27:159–165. Spanish.
   PubMedGoogle Scholar
• Oreja-Guevara C, González-Segura D, Vila C. Spasticity in multiple sclerosis: results of a patient survey. Int J Neurosci. 2013;123:400–408.
   PubMed Web of Science ®Google Scholar
• Gustavsson A, Svensson M, Jacobi F, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21:718–779.
   PubMed Web of Science ®Google Scholar
• Jorgensen N, Cabañas M, Oliva J, et al. Los costes de los cuidados informales asociados a enfermedades neurológicas discapacitantes de alta prevalencia en España. [The cost of informal care associated to incapacitating neurological disease having high prevalence in Spain.]. Neurologia. 2008;23:29–39. Spanish.
   PubMed Web of Science ®Google Scholar
• Van Den Berg B, Brouwer W, Koopmanschap M. Economic valuation of informal care. An overview of methods and applications. Eur J Health Econ. 2004;5:36–45.
   PubMedGoogle Scholar
• Glanz BI, Dégano IR, Rintell DJ, et al. Work productivity in relapsing multiple sclerosis: associations with disability, depression, fatigue, anxiety, cognition, and health-related quality of life. Value Health. 2012;15:1029–1035.
   PubMed Web of Science ®Google Scholar
• Stawowczyk E, Malinowski KP, Kawalec P, et al. The indirect costs of multiple sclerosis: systematic review and meta-analysis. Expert Rev Pharmacoecon Outcomes Res. 2015;15:759–786.
   PubMed Web of Science ®Google Scholar
• Vallejo-Torres L, García-Lorenzo B, Castilla I, et al. Valor Monetario de un Año de Vida Ajustado por Calidad: estimación empírica del coste de oportunidad en el Sistema Nacional de Salud. [Monetary Value of a Year of Life Adjusted for Quality: an empirical estimate of the opportunity cost in the National Health System] Ministerio de Sanidad, Servicios Sociales e Igualdad. Servicio de Evaluación del Servicio Canario de la Salud; 2015. Informes de Evaluación de Tecnologías Sanitarias. Spanish.
   Google Scholar
• Sacristán JA, Oliva J, Del Llano J, et al. ¿Qué es una tecnología sanitaria eficiente en España? [What is an efficient health technology in Spain?]. Gac Sanit. 2002;16:334–343. Spanish.
   PubMedGoogle Scholar
• Tremlett H, Zhao Y, Rieckmann P, et al. New perspectives in the natural history of multiple sclerosis. Neurology. 2010;74:2004–2015.
   PubMed Web of Science ®Google Scholar
• Kobelt G, Thompson A, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017;23:1123–1136.
   PubMed Web of Science ®Google Scholar
• WHO. World Health Organization. Health statistics and information systems database. Global health estimates. Global Burden of Disease 200-2012. [ cited 2016 nov]. Available from: http://www.who.int/healthinfo/global_burden_disease/gbd/en/
   Google Scholar
• Haro JM, Tyrovolas S, Garin N, et al. The burden of disease in Spain: results from the global burden of disease study 2010. BMC Med. 2014;12:236.
   PubMed Web of Science ®Google Scholar
• Gold R, Toumi M, Meesen B, et al. The payer’s perspective: what is the burden of MS and how should the patient’s perspective be integrated in health technology assessment conducted for taking decisions on access to care and treatment? Mult Scler. 2016;22(2 Suppl):60–70.
   PubMed Web of Science ®Google Scholar
• Salomon JA, Haagsma JA, Davis A, et al. Disability weights for the global burden of disease 2013 study. Lancet Glob Health. 2015;3:e712–23.
   PubMed Web of Science ®Google Scholar
• Hernández MA, Mora S. Use of the PRIMUS scale to assess quality of life in a Spanish population of multiple sclerosis patients. Neurologia. 2013;28:340–347.
   PubMed Web of Science ®Google Scholar
• Olascoaga J. Calidad de vida y esclerosis múltiple. [Quality of life and multiple sclerosis]. Rev Neurol. 2010;51: 279–288. Spanish.
   PubMed Web of Science ®Google Scholar
• Rivera-Navarro J, Benito-León J, Oreja-Guevara C, et al. Burden and health-related quality of life of Spanish caregivers of persons with multiple sclerosis. Mult Scler. 2009;15:1347–1355.
   PubMed Web of Science ®Google Scholar